Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: a case report

被引：0

作者：

Latorre, Agnese ^{[1
]}

Fioretti, Agnese Maria ^{[2
]}

Giotta, Francesco ^{[1
]}

Lorusso, Vito ^{[1
]}

机构：

[1] Ist Tumori G Paolo II, UO Oncol Med, Bari, Italy

[2] Ist Tumori G Paolo II, UO Dipartimentale Cardiol, Bari, Italy

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 24S期

关键词：

cardiological comorbidity; lenvatinib; papillary thyroid cancer; tyrosine kinase inhibitor; ATRIAL-FIBRILLATION; CANCER; INHIBITOR; MANAGEMENT; INTERVAL; FOCUS; QT;

D O I：

10.2217/fon-2019-0114

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lenvatinib significantly prolonged progression-free survival versus placebo in patients with radio-iodine refractory differentiated thyroid carcinoma. However, the primary adverse effects of any grade that occurred in >40% of patients in the lenvatinib group of the Phase III SELECT trial was hypertension (67.8%). Therefore, this drug should be used with caution in patients with cardiological morbidity. Here, we describe the case of a 73-year-old man with hypertension, obesity and chronic atrial fibrillation, who received lenvatinib for 6 months in the absence of cardiological symptoms.

引用

页码：27 / 33

页数：7

共 50 条

[1] Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report
Tori, Masayuki
Shimo, Toshirou
BMC CANCER, 2018, 18
[2] Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
Takinami, Masaki
Yokota, Tomoya
CASE REPORTS IN ONCOLOGY, 2020, 13 (02): : 522 - 527
[3] Posterior Reversible Encephalopathy Syndrome as an Adverse Effect of Lenvatinib in a Patient with Papillary Thyroid Carcinoma: A Case Report
Buenaventura, Daisy Carolina
Vargas-Sierra, Hernando
Aristizabal-Henao, Natalia
Torres-Grajales, Jose Luis
Aguilar-Londono, Carolina
Gutierrez-Restrepo, Johnayro
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2023, 21 (03)
[4] Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report
Masayuki Tori
Toshirou Shimo
BMC Cancer, 18
[5] Long-term management of recurrent papillary thyroid carcinoma treated with lenvatinib for over 5 years: a case report
Imai, Tsuneo
Kobayashi, Hironobu
Senaha, Tetsu
Imaizumi, Toshiaki
Murata, Yoshiharu
SURGICAL CASE REPORTS, 2022, 8 (01)
[6] Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis
Huang, Dongmei
Zhang, Jinming
Zheng, Xiangqian
Gao, Ming
FRONTIERS IN ENDOCRINOLOGY, 2022, 13
[7] Papillary thyroid carcinoma metastatic to the pancreas: Case report
Cho, Margaret
Acosta-Gonzalez, Gabriel
Brandler, Tamar C.
Basu, Atreyee
Wei, Xiao-Jun
Simms, Anthony
DIAGNOSTIC CYTOPATHOLOGY, 2019, 47 (03) : 214 - 217
[8] Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma
Gay, Stefano
Monti, Eleonora
Antonelli, Chiara Trambaiolo
Mora, Marco
Spina, Bruno
Ansaldo, Gianluca
Teliti, Marsida
Comina, Martina
Conte, Lucia
Minuto, Michele
Varaldo, Elisabetta
Zupo, Simonetta
Massa, Barbara
Morbelli, Silvia
Giusti, Massimo
FUTURE ONCOLOGY, 2019, 15 (24S) : 13 - 19
[9] Metastatic papillary thyroid carcinoma in the soft tissue of the breast in a male patient: A case report
Marackova, Veronika
Vomackova, Katherine
Skanderova, Daniela
Mathew, Eva
Urbankova, Marketa
Veverkova, Lucia
ONCOLOGY LETTERS, 2025, 29 (02)
[10] Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma
Boudin, Laurys
Morvan, Jean-Baptiste
Thariat, Juliette
Metivier, Denis
Marcy, Pierre-Yves
Delarbre, David
CURRENT ONCOLOGY, 2022, 29 (10) : 7718 - 7731

← 1 2 3 4 5 →